Drug updated on 11/10/2023

Dosage FormInjection (intravenous; 50 mg/ 10 mL)
Drug ClassP2Y12 platelet inhibitors
Ongoing and Completed


  • Indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Product Monograph / Prescribing Information

Document TitleYearSource
Kengreal (cangrelor) Prescribing Information.2022Chiesi USA, Inc., Cary, NC

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines